News | February 19, 2022
Natco Q3FY22 PAT up 27% to Rs 80 Cr
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
The cash consideration for the acquisition is US$ 18 million.
It is used for the treatment of advanced colorectal and gastric cancer
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
According to industry sales data, the 10mg strength of Afinitor generated annual sales of US $ 392 million during the twelve months ending July 2021
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
In 2018 NATCO and Alvogen had filed an Abbreviated New Drug Application (ANDA) with PIV certification for the generic version of the product
The company has strong product launches both in India and overseas
Subscribe To Our Newsletter & Stay Updated
